The diphtheria-tetanus-pertussis vaccine, or DTaP vaccine, is recommended for infants in the United States starting at 2 months of age.
This vaccine is one of the more difficult because, despite the 95% vaccine rate, whooping cough (whooping cough) is still very prevalent. The effectiveness of the pertussis vaccine is estimated to be anywhere from 94% to as low as 63%, depending on who you ask. It is difficult to determine that most doctors do not diagnose whooping cough as actually being whooping cough, so legitimate cases go unreported. The Centers for Disease Control and Prevention estimate that the incidence of whooping cough is 20 times higher than reported.
Changes To DPT Vaccine The most commonly used form of this vaccine is DPT, but due to the many reported cases and evidence of injury arising from pertussis, the vaccine is now manufactured with acellular. version, hence “per” in DTaP. A recent study comparing the two versions can be found in the August 2004 issue of Brebri Development.
InsertIt Package It is increasingly difficult for parents to make an informed choice about vaccinations because of these factors. the inability to determine their true effectiveness, common misconceptions about vaccine-preventable diseases and the growing list of children who have been seriously injured or even killed by vaccines. One area parents often forget to look at is the fit in the package.
Package inserts are documents included by the vaccine or drug manufacturer that contain such information as what it is, intended use, contraindications (circumstances under which the vaccine or drug should not be used) and potential Cow milk is a common baby and toddler allergen. Any child suspected of having this vaccine or diagnosed with dairy allergy should not receive this vaccine. This critical information is missing from the CDC’s DTaP Vaccine Notification (VIS), which doctors are legally required to provide Formaldehyde in DTaP
Formaldehyde is a common ingredient in vaccines and is specifically used here as an ingredient used to distort the vaccine. It has been proven that the amount is too small to pose a significant risk to vaccine recipients. It is used in various types of industries as a fungicide, germicide, disinfectant, and preservative.
Formaldehyde accumulates in construction materials and off-gases over time, making it one of the cheapest indoor pollutants. According to the National Cancer Institute, “Cancer and as a probable human carcinogen by the US Environmental Protection Agency.nasal sinuses, nasopharynx, and brain, and possibly leukemia.
The NCI also lists the health effects of lower exposure levels as watery eyes, a burning sensation in the eyes, nose and throat.
Study of the device’s effectiveness
GlaxoSmithKline studies that determine how effective their DTaP vaccine is in preventing pertussis as defined by the World Health Organization. These two studies conclude that the DTaP vaccine is 84% and 78% effective, respectively. Studies on the effectiveness of the vaccine against diphtheria and tetanus are surprisingly missing from the package insert.
Why the exclusion of Youth and Adulthood?
The DTaP package insert specifically states that INFANRIX should not be given to anyone 7. No explanation is given. A review of the package insert for other brands of DTaP, including the older DTP vaccine, reveals the same warning, even without explanation.
DTaP Warnings and Contraindications
The DTaP package insert advises that the vaccine should not be given if the recipient experiences any of the following prior to the dose:
-Encephalopathy such as coma, seizures, or loss of consciousness
-Progressive neurological disorder, such as nervous disorders or epilepsy
-Guillain-Barre syndrome within 6 weeks of the previous dose (The National-Institute of Neurological Disorders and Stroke define Guillain-Barre Syndrome as “a disorder in which the body’s immune system attacks part of the peripheral nerves. The first symptoms of this disorder include varying degrees of weakness or tingling in the legs. In many cases the weakness and abnormalities. Sensation spreads to the arms and upper body all and the patient is almost numb. /a>
-Temperature above 50 degrees in 48 hours
– Collapse or shock, as the state in 48 hours
– Persistent, inconsolable crying lasting longer than 3 hours and occurring in 48 hours
Contraindications or circumstances that mean a person should not receive the DTaP vaccine include the following:
– Latex sensitivity or allergy (latex contains parts of the syringe)
– Moderate to severe disease, with or without fever
-Bleeding disorders such as hemophilia
Not considered a potential cancer-causing agent
The package insert of the DTaP vaccine specifically states that “INFARIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.” This way, no one knows if the DTaP vaccine causes cancer or prevents fertility, and no study has been done to find out.
Additional Side Effects/Adverse Reactions to the DTaP Vaccine
The following conditions are listed as adverse reactions on the DTaP vaccine package insert. The manufacturer includes many adjuncts, even though some of these reactions are self-reported and therefore neither prove nor disprove that the vaccine actually caused them.
blush
tumor
Pain
Fever
Fussiness
Drowsiness
Poor Appetite
vomiting
A constant cry
Invasions
intestines
Swelling of the mouth
Difficulty breathing
Hypotension
Offended
Brachial neuritis
William-Barre Syndrome
Sudden Infant Death Syndrome
Cyanosis
Flow
Intussusception
Idiopathic thrombocytopenic purpura
Lymphadenopathy
Thrombocytopenia
Anaphylactic reaction
Hypersensitivity
Cellulitis
limb swelling
Convulsions
Encephalopathy
Hypotonia
Hypotonic-hyporesponsive episode
Somnolence
Anger
Respiratory Urinary Tract Infection
Erythema
Itching
Reckless
Urticaria
Ear pain
Potential Connection to Sudden Infant Death Syndrome (SIDS).
The DTaP package insert mentions some concern that the DTaP vaccine is a cause of SIDS since the vaccine is initially administered at 2 months of age, and the highest rates of SIDS occur between 2 months and 4 months of age. It is easy and quick to include the trick to discuss this statement. Various reputable research studies disagree on the link, so more research is needed to determine causality.
For More Information
It is important that individuals consider the government’s Vaccine Adverse Event Reporting System website for more information on the types of adverse reactions reported to the DTaP vaccine and how often, bearing in mind the government estimates only 10% of reactions are reported, so the actual numbers are much higher.
